Ana Torres

1 month ago | mdpi.com | Miguel Suarez |Miguel Suárez |Ana Torres |Pilar Blasco-Segura |Jorge Mateo

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

May 23, 2024 | mdpi.com | Natalia Gutierrez |Natalia Gutiérrez |Ana Torres |Inés Casimiro-Soriguer |David Aguilar-Benitez

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jan 24, 2024 | mdpi.com | Ana Torres |Isabel Almeida |Rita Oliveira

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Oct 11, 2023 | mdpi.com | Miguel Suarez |Miguel Suárez |Raquel Martínez |Ana Torres

1. IntroductionMetabolic-associated steatotic liver disease (MASLD) is a newly coined term to update the definition of non-alcoholic fatty liver disease (NAFLD). The new term aims to encompass the disease’s heterogeneity and the diversity of patients it affects. It also seeks to remove the negative connotation of the word “alcoholic” and the ambiguity of the term “non” from the patient’s perspective.

Sep 14, 2023 | mdpi.com | Miguel Suarez |Miguel Suárez |Raquel Martínez |Ana Torres

1. IntroductionMetabolic-associated steatotic liver disease (MASLD) is recent nomenclature provided for non-alcoholic fatty liver disease (NAFLD) [1]. This revised definition aims to modernize the classical definition of NAFLD, seeking to reflect the disease’s heterogeneity while relaxing restrictive alcohol consumption criteria and emphasizing the underlying metabolic dysfunction in these patients [1,2,3].